Unresolved issues in diffuse large B-cell lymphomas.

Area of Science:

• Oncology
• Hematology
• Immunotherapy

Background:

• Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) was the standard treatment for aggressive lymphomas, primarily diffuse large B-cell lymphomas (DLBCL).
• Rituximab demonstrated single-agent activity in DLBCL, prompting investigation into combination therapies.

Purpose of the Study:

• To evaluate the efficacy of combining rituximab with CHOP chemotherapy in DLBCL patients.
• To establish a new standard of care for DLBCL treatment.

Main Methods:

• A pivotal randomized trial in elderly DLBCL patients compared CHOP alone versus rituximab plus CHOP.
• Subsequent trials confirmed these findings in elderly and younger DLBCL patients.

Main Results:

• Combining rituximab with CHOP significantly improved complete remission rates, event-free survival, and overall survival compared to CHOP alone.
• Rituximab plus CHOP has become the accepted worldwide standard for DLBCL treatment across age groups.

Conclusions:

• Rituximab plus CHOP chemotherapy is the new standard of care for all DLBCL patients.
• Future research should focus on optimizing rituximab dosage, chemotherapy partners, and PET-guided therapy.
• Developing effective treatments for patients who fail rituximab-based immunochemotherapy remains a critical challenge.